|
Antimicrobial agent
|
No. of very major errors
|
No. of major errors
|
No. of minor errors
|
AST Agreement
|
Total
|
|---|
|
A
|
|
Cefoxitin (CFX)
|
1/63 (1.6 %)
|
5/29 (17.2 %)
|
2/92 (2.2 %)
|
84 (91.3 %)
|
92
|
|
Linezolid (LZ)
|
0/3
|
1/89 (1.1 %)
|
0/92
|
91 (98.9 %)
|
92
|
|
Teicoplanin (TEI)
|
0/0
|
6/92 (6.5 %)
|
3/92 (3.3 %)
|
83 (90.2 %)
|
92
|
|
Total (%)
|
1/66 (1.5 %)
|
12/210 (5.7 %)
|
5/276 (1.8 %)
|
258 (93.5 %)
|
276
|
|
B
|
|
Cefoxitin (CFX)
|
3/61 (4.7 %)
|
4/28 (14.3 %)
|
3/89 (3.4 %)
|
79 (88.7 %)
|
89
|
|
Linezolid (LZ)
|
0/3
|
0/86
|
0/89
|
89 (100 %)
|
89
|
|
Teicoplanin (TEI)
|
0/0
|
7/89 (7.9 %)
|
0/89
|
82 (92.1 %)
|
89
|
|
Total (%)
|
3/64 (4.7 %)
|
11/203 (5.4 %)
|
3/267 (1.1 %)
|
250 (93.7 %)
|
267
|
-
aUsing the results from the susceptibility testing of the bacteria by Vitek 2 as reference. In case of discrepancies, the results for the susceptibility testing were confirmed by E-test. Data are numbers (with percentages) of bacterial isolates for which the antimicrobial susceptibility testing was concordant/correct or erroneous by PR1 (A) or PR2 (B)
